CLASS ACTION REMINDER: Berger Montague Advises Hims & Hers Health Inc. (NYSE: HIMS) Investors to Inquire About a Securities Fraud Lawsuit by August 25, 2025

1. Berger Montague is investigating potential securities fraud claims against HIMS. 2. Novo Nordisk terminated its partnership with HIMS, citing deceptive marketing. 3. HIMS shares dropped over 34% following the partnership termination announcement. 4. The lawsuit alleges HIMS made misleading statements about its GLP-1 offerings. 5. Investors can claim lead plaintiff status in an upcoming class action lawsuit.

Legal

95

5m saved

Insight

Article

FAQ

Why Very Bearish?

The termination of a key partnership and a significant stock drop signal serious issues impacting HIMS. Similar cases in the past have led to prolonged declines in stock value.

How important is it?

The article directly discusses legal actions against HIMS and market concerns, indicating high relevance. Investors are likely focused on the implications for stock stability.

Why Short Term?

The immediate fallout from the announcement is expected to impact HIMS stock in the coming weeks. Historical examples show stocks often react strongly to negative partnership news.

Related Companies

NVO

PHILADELPHIA, July 10, 2025 /PRNewswire/ --

Berger Montague, a national securities litigation law firm, is investigating potential securities fraud claims against Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS).

Investor Deadline:

Investors who purchased or acquired Hims & Hers securities between April 29, 2025 and June 22, 2025 (the "Class Period") may, no later than August 25, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights, CLICK HERE.

On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers, alleging that the company engaged in deceptive marketing and sold unapproved compounded versions of semaglutide. Following the announcement, shares of Hims & Hers declined by over 34% in intraday trading, reflecting investor concerns regarding regulatory compliance and reputational risks.

This suit alleges throughout the Class Period, Hims & Hers made materially false or misleading statements or omitted material information regarding the nature and regulatory status of its GLP-1 offerings, the associated risks, and the partnership with Novo Nordisk. The firm is examining whether Hims & Hers and certain executives violated federal securities laws by making false or misleading statements to investors.

If you are a Hims & Hers investor and would like to learn more about this action, CLICK HERE or please contact Berger Montague: Andrew Abramowitz at andrew.abramowitz@bm.net or (215) 875-3015, or Caitlin Adorni at caitlin.adorni@bm.net or (267) 764-4865.

About Berger Montague

Berger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco and Chicago, has been a pioneer in securities class action litigation since its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.

For more information or to discuss your rights, please contact:

Andrew Abramowitz, Senior Counsel
Berger Montague
(215) 875-3015
andrew.abramowitz@bm.net

Caitlin Adorni
Berger Montague
(267) 764-4865
caitlin.adorni@bm.net

SOURCE Berger Montague